Esperion Therapeutics, Inc. (ESPR)

NASDAQ • Healthcare

$3.18

+$0 (+0.0%)

Market closed

Last close at July 14, 2026 at 20:00 UTC

Day Range$3.18 - $3.18

Avg. Volume (3M)0

Market Cap$661.1M

52 Week Range

$1.8$4.18

Metrics Over Time

Where the Money Goes

Q1 2026

Revenueeverything earned$80.1M100%

Gross Profitminus cost of goods$45.5M57%

In plain terms: out of every $100 in revenue, Esperion Therapeutics, Inc. currently loses $31.

Fundamentals & Financials

Revenue (TTM)

$418.2M

Net Income (TTM)

-$7.4M

EPS (TTM)

-$0.024

ROA (TTM)

-1.6%

Current Ratio

1.53

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-16.7%Q2 2025-$0.21

+88.2%Q3 2025-$0.02

-77.8%Q4 2025-$0.16

-4.3%Q1 2026$0.22

-150.0%Q2 2026-$0.1

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. is a NASDAQ-listed healthcare biotechnology company focused on developing and commercializing medicines for people with elevated low-density lipoprotein cholesterol, or LDL-C. In FY2025, it generated $403.1 million in revenue from that business, centered on prescription lipid-lowering therapies and related partnerships.

Name

Esperion Therapeutics, Inc.

CEO

Sheldon L. Koenig

Website

www.esperion.com

Industry

Healthcare

Year Founded

2008

Employees

294

Today's Snapshot

AI-generated

ESPR ended the day flat at 3.18, while its sector was weaker.

vs S&P 500 Today

Moderate Outperformance

+0.42%

Updated: September 4, 2026 at 20:08 UTC

Technical Indicators

5 Buy2 Neutral1 Sell

ESPR shows a strong, volume-supported uptrend with price above short-, medium- and longer-term moving averages and a robust ADX reading indicating trend strength. Momentum and oscillator readings are generally positive, and on-balance volume is strongly supportive, while volatility remains very low with a tight ATR around 0.02. Some overbought signals on volume-related oscillators merit caution, however the cluster of buy signals across moving averages and strong OBV underpin the positive stance. Technical takeaway: Strong trend confirmed by ADX and volume, providing a strong-buy technical profile.

All signals

EMA (5 indicators)$2.99 - $3.17
Buy
RSI (14)64.48
Neutral
Stochastic %K (14, 3, 3)88.89
Sell
MACD Level (12, 26)0.03
Neutral

Peers & Related Assets

PTCTPTC Therapeutics, Inc.

$69.3-2.9%

AGIOAgios Pharmaceuticals, Inc.

$33.1-0.1%

COLLCollegium Pharmaceutical, Inc.

$23.53-0.7%

EBSEmergent BioSolutions Inc.

$6.21-0.3%

HRTXHeron Therapeutics, Inc.

KPTIKaryopharm Therapeutics Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.